Form DEFA14A Telomir Pharmaceuticals,

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

 

Filed by the Registrant ☒

 

Filed by a Party other than the Registrant ☐

 

Check the appropriate box:

 

☐ Preliminary Proxy Statement

 

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

☐ Definitive Proxy Statement

 

☒ Definitive Additional Materials

 

☐ Soliciting Material under §240.14a-12

 

Telomir Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

 

Payment of Filing Fee (Check the appropriate box)

 

☒ No fee required

 

☐ Fee paid previously with preliminary materials

 

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Dimensional Fund Advisors Ltd. : Form 8.3 - Consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited
• Notification on the offer to exercise the pre-emptive right to acquire the new shares of AB Novaturas and of the Exemption Document for the offering and introduction thereof to trading on the regulate
• Statkraft adds first wind project to its renewable portfolio in Peru